Back

Inhibition of CKAMP44 attenuated seizure activity via protein phosphatase 3 regulatory subunit B-mediated GluA1 phosphorylation and synaptic transmission

Huang, L.; Chen, S.; Guo, H.; Zhang, H.; Wang, L.; Wang, X.; Guo, Y.; Yuan, S.; Luo, J.; Lv, Y.; Yu, W.

2026-04-23 pathology
10.64898/2026.04.21.719815 bioRxiv
Show abstract

Temporal lobe epilepsy (TLE) is a complex neurological disorder characterized by spontaneous recurrent seizures and its underlying mechanism remains elusive. This study aimed to investigate the role of cystine-knot AMPAR modulating protein 44 (CKAMP44) in the pathological process of TLE and its potential as a therapeutic target using kainic acid (KA)-induced epilepsy mouse model of TLE. Our results showed that CKAMP44 protein and mRNA expression was significantly increased and primarily localized to neurons during the chronic phase of TLE. Nkx2-1 regulated the transcription of CKAMP44 in the hippocampus brain tissues of KA-induced TLE mice. Inhibition of CKAMP44 suppressed seizure susceptibility and severity in the KA-induced epilepsy mice via behavioral and local field potential monitoring. Furthermore, inhibition of CKAMP44 decreased frequency and amplitudes of spontaneous excitatory postsynaptic currents indicating that the excitatory synaptic transmission was reduced in an in vitro epilepsy model. Mechanistically, inhibition of CKAMP44 specifically upregulated the membrane surface expression of GluA1 and the phosphorylation level of GluA1-ser831 by downregulating protein phosphatase 3 regulatory subunit B(PPP3r2) expression. Overexpression of PPP3r2 downregulated the phosphorylation level and surface expression of GluA1, which ultimately exacerbated the seizure activity suppressed by CKAMP44 knockdown. Collectively, our results indicate that CKAMP44 may be a potential therapeutic target for the treatment of TLE.

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

1
PLOS ONE
4510 papers in training set
Top 20%
9.2%
2
Experimental Neurology
57 papers in training set
Top 0.1%
6.4%
3
Brain
154 papers in training set
Top 0.9%
6.4%
4
Cell Discovery
54 papers in training set
Top 0.7%
6.4%
5
Epilepsia
49 papers in training set
Top 0.4%
3.6%
6
PLOS Neglected Tropical Diseases
378 papers in training set
Top 2%
3.6%
7
Journal of Clinical Investigation
164 papers in training set
Top 1%
3.6%
8
National Science Review
22 papers in training set
Top 0.3%
3.6%
9
PLOS Pathogens
721 papers in training set
Top 4%
2.8%
10
Science Bulletin
22 papers in training set
Top 0.2%
2.6%
11
Human Molecular Genetics
130 papers in training set
Top 1%
2.4%
50% of probability mass above
12
eLife
5422 papers in training set
Top 34%
2.4%
13
The Lancet Infectious Diseases
71 papers in training set
Top 1%
1.7%
14
Neurobiology of Disease
134 papers in training set
Top 3%
1.7%
15
Scientific Reports
3102 papers in training set
Top 58%
1.7%
16
The FASEB Journal
175 papers in training set
Top 1%
1.5%
17
Epilepsy Research
12 papers in training set
Top 0.2%
1.3%
18
Gastroenterology
40 papers in training set
Top 1%
1.3%
19
Advanced Science
249 papers in training set
Top 13%
1.3%
20
JCI Insight
241 papers in training set
Top 5%
1.2%
21
International Journal of Molecular Sciences
453 papers in training set
Top 10%
1.2%
22
Annals of Neurology
57 papers in training set
Top 2%
1.2%
23
Frontiers in Genetics
197 papers in training set
Top 6%
1.2%
24
Frontiers in Pharmacology
100 papers in training set
Top 3%
1.1%
25
iScience
1063 papers in training set
Top 29%
0.8%
26
Frontiers in Microbiology
375 papers in training set
Top 8%
0.8%
27
Pharmacological Research
15 papers in training set
Top 0.2%
0.8%
28
Cells
232 papers in training set
Top 6%
0.8%
29
International Immunopharmacology
15 papers in training set
Top 0.5%
0.8%
30
Gene
41 papers in training set
Top 2%
0.8%